Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

92.32 +1.91 (+2.11%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,999,066
Open 90.79
Bid (Size) 92.32 (5)
Ask (Size) 92.60 (5)
Prev. Close 90.41
Today's Range 90.68 - 92.87
52wk Range 15.32 - 92.87
Shares Outstanding 2,531,374,696
Dividend Yield 2.82%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
4 Stocks Moved By Traders On 'Fast Money: Halftime Report'
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. The... 
Via Benzinga
Merck, Athenex Join Forces To Evaluate Oraxol/Keytruda Combo In Lung Cancer
 
Via Benzinga

Performance

YTD
+20.10%
+20.10%
1 Month
+7.26%
+7.26%
3 Month
+20.73%
+20.73%
6 Month
+10.31%
+10.31%
1 Year
+15.59%
+15.59%

More News

Read More
7 Retirement Stocks for Steady Long-Term Income Growth
Via InvestorPlace
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Via Talk Markets
Stocks Are Undervalued
Via Talk Markets
7 Profitable Places to Hide Your Money During a Bear Market
Via InvestorPlace
CNBC's Final Trades: Charles Schwab And These 3 Medical Stocks
Via Benzinga
15 Stocks Moved By Traders on 'Fast Money: Halftime Report'
Via Benzinga
Analyzing Merck & Co's Short Interest
Via Benzinga
Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)
From Merck & Co., Inc.
Via Business Wire
Dow Giants Chevron, Merck Lead Five Stocks Showing Strength In A Bad Market
Via Investor's Business Daily
7 Defensive Dividend Healthcare Stocks to Buy Now
Via InvestorPlace
This Company Is Reportedly Solving Bedroom Performance Issues Behind Closed Doors
Via Benzinga
Organon Easily Beats First-Quarter Expectations Despite Nexplanon Slip-Up
Via Investor's Business Daily
CNBC's Final Trades: Honeywell International, Merck And More
Via Benzinga
4 Stocks Moved By Traders on 'Fast Money: Halftime Report'
Via Benzinga
Merck to Participate in Bank of America Securities 2022 Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Safe Stocks to Buy in May 2022
Via InvestorPlace
Exxon Mobil, General Dynamics Lead Five Stocks Near Buy Points Without This Big Risk
Via Investor's Business Daily
The Nasdaq, S&P 500 And Dow Took A Big Dive In April
Via Benzinga
Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review
Via Investor's Business Daily
What 7 Analyst Ratings Have To Say About Merck & Co
Via Benzinga
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Via Benzinga
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer
From Merck & Co., Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.